Ovid Therapeutics Inc.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$151M
↑+63.8% +$59Mvs FY2024
Total Liabilities
$20M
↓-15.3% -$4Mvs FY2024
Equity
$131M
↑+91.5% +$62Mvs FY2024
Cash
$13M
↓-50.0% -$13Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $151M | $92M |
| Current Assets | $74M | $56M |
| Cash | $13M | $26M |
| ST Investments | $0 | $0 |
| Receivables | $0 | $0 |
| Inventory | $0 | $0 |
| Other Current | $61M | $30M |
| Non-Current Assets | $77M | $36M |
| PPE | $252K | $433K |
| Goodwill | $0 | $0 |
| Intangibles | $0 | $100K |
| Investments | $0 | $21M |
| Other Non-Current | $76M | $15M |
| Total Liab+Eq | $151M | $92M |
| Current Liab. | $8M | $11M |
| Accounts Payable | $2M | $3M |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $0 | $0 |
| Other CL | $6M | $7M |
| Non-Current Liab. | $12M | $13M |
| Long-Term Debt | $0 | $0 |
| Other LT Liab. | $12M | $13M |
| Equity | $131M | $68M |
| Retained Earnings | $322M | $304M |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · OVID · Comparing FY2025 vs FY2024